ADCETRIS 50 mg powder for concentrate for solution for infusion
Sponsors
University College London, Merck Sharp & Dohme LLC, Lysarc, Seagen Inc., Takeda Development Center Americas Inc.
Conditions
Advanced Classical Hodgkin LymphomaAdvanced Stage of Hodgkin LymphomaAdvanced stage Hodgkin LymphomaCancerClassical Hodgkin LymphomaDiffuse large B-cell lymphoma (DLBCL)Hodgkin LymphomaHodgkin lymphoma
Phase 1
Phase 2
Multiple Part Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma Subjects
CompletedCTIS2023-503387-16-00
Start: 2021-07-13End: 2024-08-23Target: 22Updated: 2024-06-10
A Phase II Open Label Study of Brentuximab Vedotin in Combination with CHEP in Patients with Previously Untreated CD30-expressing Peripheral T-cell Lymphomas (PTCL)
Not yet recruitingCTIS2024-511567-28-01
Target: 33Updated: 2024-08-27
EORTC-1537-LYMG: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study
Active, not recruitingCTIS2023-508478-27-00
Start: 2019-07-30Target: 7Updated: 2026-01-23
A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentuximab Vedotin Consolidation (instead of Autologous Hematopoietic Stem Cell Transplantation) in Those who Attained a Metabolic Complete Remission after Salvage Therapy
Not yet recruitingCTIS2024-516149-38-00
Target: 149Updated: 2025-01-22
HOVON 136 NHL: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (RDHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in first relapse who are eligible for high dose treatment followed by autologous stem cell transplantation.
Active, not recruitingCTIS2023-510556-22-00
Start: 2018-03-05Target: 36Updated: 2024-11-25
Phase 3
A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
CompletedCTIS2022-500400-22-00
Start: 2016-06-23End: 2025-12-10Target: 114Updated: 2025-11-20
RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
RecruitingCTIS2022-500031-37-00
Start: 2024-04-08Target: 289Updated: 2025-06-23
A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
Active, not recruitingCTIS2023-506419-16-00
Start: 2013-01-08Target: 448Updated: 2025-12-15
HD21 for advanced stages - Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 4-6 cycles of escalated BEACOPP with 4-6 cycles of BrECADD
CompletedCTIS2024-518022-33-00
Start: 2016-07-15End: 2024-12-01Target: 1320Updated: 2024-11-19